Coreleader is pleased to announce the great news of the approval of HEMO-bandage patent by US patent office today. This is a positive gesture reflecting the claim filed by Coreleader of chitosan’s fiber incorporation know-how is recognized by US patent office as an innovation and leading technology. Hence, the approval would escalate further differentiation between the classic impregnation vs. innovative incorporation and the benefit induced by the innovation, above all safety.  

All the leading pre-hospital hemostatic agents in the market today impregnate the hemostatic chemicals, including but not limited to kaolin and chitosan, on the surface of a non-woven fabric. In the case the traumatic wound has massive bleeding, the chemical may dissolve into the blood when it is packed to the open wound with blood pool. By the time compression starts, the contaminated blood may be pushed back to the blood vessel and hence, goes into the circulation system leading to undesirable side effects.

Other than the cytotoxicity, distal thrombosis was also mentioned by US Army Institute of Surgical Research (USAISR) in their papers published in 2010 and 2011. HEMO has no such concerns because it is free of cytotoxicity and its chitosan incorporation does not leave dust or debris to the wound that may trigger thrombosis.

Coreleader Biotech is committed to the supply of safe and effective hemostatic dressing on lethal hemorrhage to save lives. The approval by US patent office has paved the way to achieve its mission faster.

Congratulations.